Huntsville, Ala. — The HudsonAlpha Institute for Biotechnology today announced it has entered into a letter of intent with Epitomics, Inc., the leading rabbit monoclonal antibody technology company, to engage in a multi-phase collaboration where parties will jointly develop and market rabbit monoclonal antibodies and a proteomics database for public distribution.

Under the collaboration terms, the HudsonAlpha Institute for Biotechnology will generate an IHC-based proteomic database in human tissues while Epitomics will apply its proprietary rabbit monoclonal antibody technology for the common goals of the multi-phase collaboration. HudsonAlpha has issued a grant to Applied Genomics Inc. of Huntsville, Ala., to carry out a pilot project already underway. The parties are collaborating to determine the practicality and cost to generate monoclonal antibodies to all human proteins screened specifically for their utility in IHC.

Applied Genomics CSO, Dr. Douglas T. Ross also speaking on behalf of HudsonAlpha stated, “We are very excited to contribute to an initiative to generate a definitive database of protein expression across the human proteome as well as generate high quality IHC reagents widely available for further research. Rabbit monoclonal technology combined with AGI’s pipeline for immunohistochemistry data generation, and HudsonAlpha’s commitment to place data in the public domain, will catalyze biomarker research towards the goal of understanding the complicated role of disease classification in clinical decision making.”

Epitomics’ CEO Dr. Guo-Liang Yu is enthusiastic about this partnership, stating, “The collaboration with HudsonAlpha Institute for Biotechnology provides us a new technology platform with a combined force to allow Epitomics to serve the industry needs better. The collaboration will expand Epitomics’ reagent business offering and strengthen Epitomics’ ability to provide unique solutions to our customers.”

The HudsonAlpha Institute of Biotechnology is a nonprofit research institute located in Huntsville, Ala. The three-fold mission of the Institute are to foster biotechnology-based research into why disease occurs and cost effective ways to treat it, to lead to commercializing biotechnology discoveries to stimulate economic development in Alabama, and to inspire Alabama’s youth to seek careers in science by offering them access to cutting edge biotechnology courses through distance learning. www.hudsonalpha.org

Epitomics, Inc. is an emerging biotechnology company that develops and commercializes a proprietary rabbit monoclonal antibody technology for research community and diagnostic as well as therapeutic companies through licensing, services and sales of its products. The Company has headquarters in Burlingame, California, and a wholly owned subsidiary in Hangzhou, the People’s Republic of China.

Applied Genomics, Inc. is an emerging biotechnology company that is translating insights from gene expression-based classification of cancer into immunohistochemistry-based diagnostic tests for stratification of carcinoma. The company has headquarters in Huntsville, Alabama and a research division located in Sunnyvale, California.

Huntsville, Ala. – The HudsonAlpha Institute for Biotechnology today announced it has entered into a letter of intent with Epitomics, Inc., the leading rabbit monoclonal antibody technology company, to engage in a multi-phase collaboration where parties will jointly develop and market rabbit monoclonal antibodies and a proteomics database for public distribution. Under the collaboration terms, the HudsonAlpha Institute for Biotechnology will generate an IHC-based proteomic database in human tissues while Epitomics will apply its proprietary rabbit monoclonal antibody technology for the common goals of the multi-phase collaboration. HudsonAlpha has issued a grant to Applied Genomics Inc. of Huntsville, Alabama to carry out a pilot project already underway. The parties are collaborating to determine the practicality and cost to generate monoclonal antibodies to all human proteins screened specifically for their utility in IHC.

Applied Genomics CSO, Dr. Douglas T. Ross also speaking on behalf of HudsonAlpha stated, “We are very excited to contribute to an initiative to generate a definitive database of protein expression across the human proteome as well as generate high quality IHC reagents widely available for further research. Rabbit monoclonal technology combined with AGI’s pipeline for immunohistochemistry data generation, and HudsonAlpha’s commitment to place data in the public domain, will catalyze biomarker research towards the goal of understanding the complicated role of disease classification in clinical decision making.”

Epitomics’ CEO Dr. Guo-Liang Yu is enthusiastic about this partnership, stating, “The collaboration with HudsonAlpha Institute for Biotechnology provides us a new technology platform with a combined force to allow Epitomics to serve the industry needs better. The collaboration will expand Epitomics’ reagent business offering and strengthen Epitomics’ ability to provide unique solutions to our customers.”

The HudsonAlpha Institute of Biotechnologyis a not-for-profit research Institute located in Huntsville Alabama. The three-fold mission of the Institute are to foster biotechnology-based research into why disease occurs and cost effective ways to treat it, to lead to commercializing biotechnology discoveries to stimulate economic development in Alabama, and to inspire Alabama’s youth to seek careers in science by offering them access to cutting edge biotechnology courses through distance learning. www.hudsonalpha.org

Epitomics, Inc. is an emerging biotechnology company that develops and commercializes a proprietary rabbit monoclonal antibody technology for research community and diagnostic as well as therapeutic companies through licensing, services and sales of its products. The Company has headquarters in Burlingame, California, and a wholly owned subsidiary in Hangzhou, the People’s Republic of China.

Applied Genomics, Inc. is an emerging biotechnology company that is translating insights from gene expression-based classification of cancer into immunohistochemistry-based diagnostic tests for stratification of carcinoma. The company has headquarters in Huntsville, Alabama and a research division located in Sunnyvale, California.

Media Contact: Beth Pugh
bpugh@hudsonalpha.org
256-327-0443

About HudsonAlphaHudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological problems. Its mission is three-fold: sparking scientific discoveries that can impact human health and well-being; fostering biotech entrepreneurship; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus allow serendipity to yield results in medicine and agriculture. Since opening in 2008, HudsonAlpha, under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, has built a name for itself in genetics and genomics research and biotech education, and boasts 26 biotech companies on campus.